International Cancer Conference Journal

, Volume 8, Issue 4, pp 164–169 | Cite as

Systemic steroid treatment can desensitize the skin reaction due to regorafenib in a recurrence colorectal cancer patient

  • Keita TashiroEmail author
  • Eiji Shinto
  • Yoshiki Kajiwara
  • Satsuki Mochizuki
  • Koichi Okamoto
  • Aya Nishizawa
  • Takahiro Satoh
  • Yoji Kishi
  • Hideki Ueno
Case report


Oral intake of regorafenib has been shown to have survival benefits in patients with metastatic colorectal cancer progressing on standard therapies. However, because of adverse effects, the patients sometimes cannot continue treatment with regorafenib. Currently, there is no established supportive therapy that can be performed to aid in continuing regorafenib intake under these problematic conditions. We report the case of a 59-year-old Japanese woman diagnosed with recurrence after curative operation for sigmoid colon cancer (T3N2aM0, Stage IIIC). Despite undergoing multiple lines of standard chemotherapy, disease control could not be maintained. Consequently, regorafenib was started as a late-line treatment. However, after 2 weeks, the patient experienced regorafenib-induced serious erythema multiforme; thus, regorafenib was discontinued and oral prednisolone was started. Regorafenib administration was resumed when the adverse effects resolved and prednisolone was stopped, but skin rash rapidly reappeared. Prednisolone treatment was reintroduced, which cured the rash; thus, after the third attempt to administer regorafenib, prednisolone was continuously administered. There was no relapse of the rash under prednisolone administration, and the patient received a total of 13 courses of regorafenib. Moreover, the metastatic lesions that had started to regrow at the end of the regorafenib therapy showed good response to the rechallenge chemotherapy of folinic acid, fluorouracil, and irinotecan therapy with panitumumab. The sequence of therapies possibly had a positive impact on the patient’s long survival of 30 months after the regorafenib treatment. Systemic administration of steroid is considered as a promising option as a supportive therapy for continuing regorafenib treatment in patients experiencing a severe skin rash.


Metastatic colorectal cancer Regorafenib Erythema multiforme Rechallenge chemotherapy Continuous steroid intake Supportive therapy 



This report was not funded.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

The patient has already died, but informed consent was obtained from the bereaved in this case report. There is no identifying information about patient in the article.


  1. 1.
    Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicenter, randomized, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312CrossRefGoogle Scholar
  2. 2.
    Krishnamoorthy SK, Relias V, Sebastian S et al (2015) Management of regorafenib-related toxicities: a review. Therap Adv Gastroenterol 8:285–297CrossRefGoogle Scholar
  3. 3.
    Brierley JD, Gospodarowicz MK, Wittekind C (eds) (2017) The TNM classification of malignant tumours, 8th edn. Wiley-Blackwell, United States of AmericaGoogle Scholar
  4. 4.
    Watanabe T, Muro K, Ajioka Y et al (2018) Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for treatment of colorectal cancer. Int J Clin Oncol 23:1–34CrossRefGoogle Scholar
  5. 5.
    Matsunaga M, Ushijima T, Fukahori M et al (2017) Erythema multiforme induced by regorafenib. J Gen Fam Med 18:90–91CrossRefGoogle Scholar
  6. 6.
    Mii Y, Fukuoka E, Murata K et al (2014) A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer. Gan To Kagaku Ryoho 41:1841–1843Google Scholar
  7. 7.
    Santini D, Vincenzi B, Addeo R et al (2012) Cetuximab rechallenge in metastatic colorectal cancer patients: How to come away from acquired resistance? Ann Oncol 23:2313–2318CrossRefGoogle Scholar
  8. 8.
    Tonini G, Imperatori M, Vincenzi B et al (2013) Rechallenge therapy and treatment holiday: different strategies in management of metastatic colorectal cancer. J Exp Clin Cancer Res 32:92CrossRefGoogle Scholar
  9. 9.
    Artale S, Sartore-Bianchi A, Veronese SM et al (2006) Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. J Clin Oncol 26(25):4217–4219CrossRefGoogle Scholar
  10. 10.
    Baldus SE, Schaefer KL, Engers R et al (2010) Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 16(3):790–799CrossRefGoogle Scholar
  11. 11.
    Bertocchi P, Aroldi F, Prochilo T et al (2017) Chemotherapy rechallenge after reforafenib treatment in metastatic colorectal cancer: still hope after the last hope? J Chemother 29:102–105CrossRefGoogle Scholar
  12. 12.
    Kidd MT, Wilcox RE, Rogers J et al (2015) Efficacy of chemotherapy after treatment with regorafenib in metastaic colorectal cancer (mCRC). J Clin Oncol 33:678CrossRefGoogle Scholar
  13. 13.
    Naoto T, Koji M, Takuma O et al (2015) 4-step 4-h carboplatin desensitization protocol for patients with gynecological malignancies showing platinum hypersensitivity: a retrospective study. Int J Clin Oncol 20(3):566–573CrossRefGoogle Scholar
  14. 14.
    Yoichiro Y, Keiji H, Hiroshi M et al (2015) A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial. Drug Des Devel Ther 9:6067–6073Google Scholar
  15. 15.
    Hisashi N, Etsuro H, Koji T et al (2014) A case of desensitization of sorafenib after tumor lysis syndrome and erythema multiform in the patient with advanced hepatocellular carcinoma. Kanzo 55:221–227CrossRefGoogle Scholar
  16. 16.
    Bauer C, Przybilla B, Rueff F (2008) Severe cutaneous reaction to sorafenib: induction of tolerance. Acta Derm Venereol 88:627–628Google Scholar

Copyright information

© The Japan Society of Clinical Oncology 2019

Authors and Affiliations

  1. 1.Department of SurgeryNational Defense Medical College HospitalTokorozawaJapan
  2. 2.Department of DermatologyNational Defense Medical College HospitalTokorozawaJapan

Personalised recommendations